本文關(guān)鍵詞： 免疫檢查點阻斷藥物 療效 耐藥 腫瘤相關(guān)因素 非腫瘤相關(guān)因素　出處：《腫瘤防治研究》2017年08期 　論文類型：期刊論文

【摘要】：免疫治療可以在晚期癌癥患者身上引起比常規(guī)化療更大的持續(xù)應(yīng)答,然而,這一應(yīng)答僅發(fā)生在相對少部分患者身上。免疫治療的陽性反應(yīng)通常依賴于腫瘤細胞與腫瘤微環(huán)境(TME)內(nèi)免疫調(diào)節(jié)的相互作用,同時受到腫瘤細胞自身及宿主因素的影響。影響免疫檢查點阻斷藥物(ICB)療效的腫瘤相關(guān)因素包括突變負荷、致癌信號、DNA MMR缺陷的影響、死亡前細胞應(yīng)激和損傷相關(guān)分子模式、PD-L1的表達等因素;非腫瘤相關(guān)因素主要包括外周和腫瘤內(nèi)淋巴細胞、病毒等因素。影響ICB耐藥的腫瘤相關(guān)因素主要包括代謝、表觀遺傳沉默趨化因子分泌、Ⅰ型干擾素信號轉(zhuǎn)導(dǎo)、腸道微生物、慢性感染、年齡、吸煙史等。多種策略的聯(lián)合使用,是未來的治療趨勢,通常會提高療效,但同時也可能增加毒性。
[Abstract]:Immunotherapy can cause sustained response, greater than the conventional chemotherapy in advanced cancer patients. However, this response occurs only in a relatively small part of the patients. The positive reaction of immunotherapy usually depend on tumor cells and tumor microenvironment (TME) interactions in immune regulation, and also affected by tumor cells self and host factors. The influence of immune checkpoint blocking drugs (ICB) tumor related factors including the effect of mutation load, carcinogenic effects of DNA signal, MMR defect, before the death of cell stress and damage associated molecular patterns, the expression of PD-L1 and other factors; related factors of non tumor including peripheral lymphocytes and tumor virus, etc. factors. Factors affecting ICB resistant tumors including metabolism, epigenetic silencing chemokine secretion, type I interferon signal transduction, intestinal microflora, chronic infection, age, smoking history Combined use of a variety of strategies is a future trend of treatment, which usually improves the efficacy, but it may also increase toxicity.

【作者單位】： 湖北省腫瘤醫(yī)院胸部腫瘤內(nèi)科一病區(qū);黃岡市中醫(yī)醫(yī)院腫瘤科;
【分類號】：R730.51
，

本文編號：1553950